By blocking PD-L1 on tumor cells and PD-1 on T cells, immunotherapy can effectively restore T cell function and enhance the immune system’s ability to recognize and eliminate tumor cells, thereby achieving anti-tumor effects (Chen et al., 2022; Ren et al., 2022). This evidence concerns the gene PDCD1 and neoplasm.